Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters

Abstract

Background/aim: Adropin is a peptide-structure hormone that plays a role in preventing the development of insulin resistance, which has been linked to obesity and metabolic regulation. The purpose of this study is to assess serum adropin levels and their relationship with metabolic parameters in psoriasis vulgaris patients both with and without metabolic syndrome (MetS). Methods: Fifty-three patients and twenty-six healthy controls were included in this study. Serum adropin levels, fasting blood glucose, fasting plasma insulin, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, and triglyceride levels of all participants were analyzed. Enzyme-linked immunosorbent assay was used to measure serum adropin levels. Results: Serum adropin levels in psoriatic patients without MetS were 2.94±0.56 ng/ml, in psoriasis patients with MetS were 2.49±0.77 ng/ml and were 3.37±0.71 ng/ml in control group. Multivariate logistic regression analysis was used to evaluate adropin decreases in psoriasis patients as an independent predictor in terms of the presence of MetS. Conclusion: The serum levels of adropin in psoriasis patients were significantly lower in the presence of MetS, and this decrease was more prominent than in those without MetS. Adropin may be a responsible factor for metabolic disorders and the development of MetS in psoriasis patients. Key words: Psoriasis, metabolic syndrome, adropin